secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001048477-23-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin reports record Q4 revenues $537.5M (+19% YoY); guides 2023 total rev $2.375-2.5B
--------------------------------------------------------------------------------

- Q4 total revenues $537.5M, up 19% YoY; full year $2.096B, up 14%.
- GAAP net loss improved to $0.2M in Q4 from $57.9M loss; full year net income $141.6M.
- VOXZOGO full year revenues $169.1M, up from $5.9M in 2021; 1,264 children treated as of Jan 2023.
- 2023 guidance: total rev $2.375-2.5B, GAAP net income $155-205M, non-GAAP EPS $1.80-2.05.
- ROCTAVIAN 2023 revenue guidance $100-200M; FDA PDUFA date March 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847723000005/0001048477-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847723000005/bmrn-20230227.htm
  HTML page:      https://secwatch.observer/filing/0001048477-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer